Recmed Secures $12.9 million in Funding through FUNDINNO PLUS+ Service
Recently, Recmed, a biopharmaceutical venture based in Machida City, Tokyo, announced a successful fundraising of about 12.9 billion yen (approximately $12.9 million). This notable achievement was reached through the platform FUNDINNO PLUS+, which allows for direct investment from accredited investors. Given the surge in high-value fundraising cases like Recmed's, the cumulative amount of transactions facilitated by FUNDINNO PLUS+ has surpassed 8 billion yen, totaling around 8.9 billion yen, showcasing a vibrant investment atmosphere in Japan's startup and biotech sectors.
Recmed distinguishes itself as a rare entity among domestic drug development ventures. They manage the entire process from clinical trial planning to obtaining manufacturing and marketing approvals, and following up with post-launch sales. This integrated approach has led to the success of bringing two treatments to market so far.
The company is currently advancing four pipelines, including treatments for three rare diseases and osteoarthritis, with the latter now in Phase 3 clinical trials. Recmed is ambitiously targeting a market launch within Japan for this osteoarthritis medication by 2029. Their mission is to deliver "100-year medicines" globally, resolving both drug development and the daunting issue known as drug lag.
CEO Masashi Matsumoto expressed the company's commitment to developing urgently needed medicines. He noted that Recmed has successfully launched two rare disease treatments that were already approved abroad but previously unapproved domestically. Matsumoto emphasized the pressing need for treatments in Japan, particularly for osteoarthritis, which affects approximately 8 million patients in an aging society.
With clinical trials for this treatment now in Phase 3, there's a growing requirement for development funds. In such challenging times, particularly for late-stage biotech ventures struggling to secure funding, Recmed turned to FUNDINNO PLUS+. Matsumoto highlighted that the support from various investors has injected significant momentum into their development projects, raising a total of approximately 12.98 billion yen. He expressed gratitude for the investor confidence and the associated responsibility this brings.
FUNDINNO PLUS+ is a unique service that enables startups and ventures to secure large-scale funding while allowing investors to invest in promising, relatively soon-to-IPO companies. By registering as specific investors, individuals can connect with emerging, non-listed firms poised for significant growth. This approach is seen as an appealing option given the balance of risk and return.
The funding secured by Recmed utilized the Specific Investor Stock System (J-Ships), allowing for a streamlined issuance and circulation of shares and investment trusts targeted at professional investors through brokerage channels.
Founded to democratize venture funding in Japan, FUNDINNO aims to erase the information and opportunity gap for all entrepreneurs and investors. The platform connects businesses in need of funding with investors who wish to support promising ventures. It operates various services, including FUNDINNO MARKET for trading unlisted stocks online, and FUNDOOR, a management platform designed specifically for venture companies.
With these innovations, FUNDINNO is striving to create a future where every entrepreneur can challenge the status quo with a fair chance.
Recmed's fundraising success is an encouraging sign for Japan's startup scene, particularly in the biotech sector. As the company continues its journey towards impactful medicine development, its achievements are likely to inspire both investors and other biotech firms looking to innovate and expand their horizons.
Overview of Recmed
Recmed distinguishes itself as a rare entity among domestic drug development ventures. They manage the entire process from clinical trial planning to obtaining manufacturing and marketing approvals, and following up with post-launch sales. This integrated approach has led to the success of bringing two treatments to market so far.
The company is currently advancing four pipelines, including treatments for three rare diseases and osteoarthritis, with the latter now in Phase 3 clinical trials. Recmed is ambitiously targeting a market launch within Japan for this osteoarthritis medication by 2029. Their mission is to deliver "100-year medicines" globally, resolving both drug development and the daunting issue known as drug lag.
Insights from CEO Masashi Matsumoto
CEO Masashi Matsumoto expressed the company's commitment to developing urgently needed medicines. He noted that Recmed has successfully launched two rare disease treatments that were already approved abroad but previously unapproved domestically. Matsumoto emphasized the pressing need for treatments in Japan, particularly for osteoarthritis, which affects approximately 8 million patients in an aging society.
With clinical trials for this treatment now in Phase 3, there's a growing requirement for development funds. In such challenging times, particularly for late-stage biotech ventures struggling to secure funding, Recmed turned to FUNDINNO PLUS+. Matsumoto highlighted that the support from various investors has injected significant momentum into their development projects, raising a total of approximately 12.98 billion yen. He expressed gratitude for the investor confidence and the associated responsibility this brings.
What is FUNDINNO PLUS+?
FUNDINNO PLUS+ is a unique service that enables startups and ventures to secure large-scale funding while allowing investors to invest in promising, relatively soon-to-IPO companies. By registering as specific investors, individuals can connect with emerging, non-listed firms poised for significant growth. This approach is seen as an appealing option given the balance of risk and return.
The funding secured by Recmed utilized the Specific Investor Stock System (J-Ships), allowing for a streamlined issuance and circulation of shares and investment trusts targeted at professional investors through brokerage channels.
About FUNDINNO
Founded to democratize venture funding in Japan, FUNDINNO aims to erase the information and opportunity gap for all entrepreneurs and investors. The platform connects businesses in need of funding with investors who wish to support promising ventures. It operates various services, including FUNDINNO MARKET for trading unlisted stocks online, and FUNDOOR, a management platform designed specifically for venture companies.
With these innovations, FUNDINNO is striving to create a future where every entrepreneur can challenge the status quo with a fair chance.
Conclusion
Recmed's fundraising success is an encouraging sign for Japan's startup scene, particularly in the biotech sector. As the company continues its journey towards impactful medicine development, its achievements are likely to inspire both investors and other biotech firms looking to innovate and expand their horizons.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.